TY - JOUR
T1 - Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI)
T2 - A prespecified prospective register from the DAPT-STEMI trial
AU - Postma, Warner
AU - Fabris, Enrico
AU - van der Ent, Martin
AU - Hermanides, Rik
AU - Buszman, Pawel
AU - von Birgelen, Clemens
AU - Cook, Stéphane
AU - Wedel, Hans
AU - De Luca, Giuseppe
AU - Delewi, Ronak
AU - Zijlstra, Felix
AU - Kedhi, Elvin
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.
AB - Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.
KW - Acute myocardial infarction
KW - Antiplatelet therapy
KW - Coronary artery disease
KW - Drug-eluting stents (DES)
KW - Stent thrombosis
KW - UT-Hybrid-D
UR - http://www.scopus.com/inward/record.url?scp=85068619480&partnerID=8YFLogxK
U2 - 10.1002/ccd.28376
DO - 10.1002/ccd.28376
M3 - Article
AN - SCOPUS:85068619480
VL - 95
SP - 706
EP - 710
JO - Catheterization and cardiovascular interventions
JF - Catheterization and cardiovascular interventions
SN - 1522-1946
IS - 4
ER -